ABL Diagnostics: management transactions · France · AMF

About ABL Diagnostics

ABL Diagnostics is a French molecular diagnostics company listed on Euronext Paris under ticker/ISIN FR001400AHX6. The group develops, manufactures and commercializes microbiology and molecular biology solutions for laboratories, hospitals and specialized healthcare providers focused on infectious diseases. Its business model sits in a high-value niche that combines diagnostic assays, sequencing-based genotyping tools and proprietary software, with a particularly strong focus on pathogen resistance profiling and patient follow-up. The company’s roots date back to 2015, when ABL SA created ABL France, which later became the operational core of the diagnostic perimeter. ABL Diagnostics is now described as the listed subsidiary and sole publicly traded entity of the Luxembourg-based Advanced Biological Laboratories SA group. Over time, the group has built a proprietary technology platform around DeepChek®, then expanded into complementary molecular and digital solutions. It also established ABL USA Inc. to support commercialization in North America, while maintaining commercial reach across Europe, Africa and additional international markets. DeepChek® is the flagship product family and central platform, based on Sanger sequencing and next-generation sequencing (NGS) for genotyping applications. It is used in particular for HIV, tuberculosis, hepatitis viruses and other infectious disease targets. The product suite also includes UltraGene®, which provides RT-PCR molecular detection solutions, as well as software and digital tools for analysis, data hosting, laboratory automation and the NADIS® computerized medical record. NADIS® is an important strategic asset: it is a specialty electronic health record designed for infectious disease patients and is reported by the company to be used in more than 200 hospitals in France and French-speaking Africa. ABL Diagnostics targets an international market, with sales and partnership networks spanning France, Europe, French-speaking Africa and North America. The company emphasizes distributor partnerships and commercial expansion to broaden access to its assays and software worldwide. Its competitive position is that of a specialized integrated molecular diagnostics player, capable of bundling reagents, sequencing workflows, data tools and clinical follow-up software. Notable features of the business include recurring subscription revenue from NADIS® and a product focus on clinically relevant, high-need indications such as HIV and tuberculosis, where diagnostic precision, speed and treatment resistance monitoring remain essential.